NYSE:AIM AIM ImmunoTech - AIM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.48 +0.01 (+2.01%) (As of 03/17/2023 08:53 PM ET) Add Compare Share Share Today's Range$0.47▼$0.4950-Day Range$0.45▼$0.7752-Week Range$0.29▼$1.38Volume117,000 shsAverage Volume269,596 shsMarket Capitalization$23.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media About AIM ImmunoTech (NYSE:AIM) StockAIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.Read More Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address AIM Stock News HeadlinesMarch 17, 2023 | baystreet.caBiotech Sector Delivering Increased Optimism in Battle Against Pancreatic CancerMarch 16, 2023 | tmcnet.comAIM ImmunoTech Announces Late-Breaking Presentation at theMarch 20, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 16, 2023 | finance.yahoo.comAIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus DiseaseMarch 8, 2023 | tmcnet.comAIM ImmunoTech Announces Publication of New Analysis ofMarch 6, 2023 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Issues Letter to StockholdersFebruary 28, 2023 | finance.yahoo.comAIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting PatientsFebruary 17, 2023 | tmcnet.comAIM ImmunoTech to Participate in Solve M.E.March 20, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 17, 2023 | finance.yahoo.comAIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”February 17, 2023 | marketwatch.comWarts Therapeutics Market Size 2023 : Emerging Technologies, Opportunity and Forecast to 2028January 17, 2023 | msn.comAIM ImmunoTech gains on research deal for lead assetJanuary 17, 2023 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical CenterJanuary 17, 2023 | proactiveinvestors.comAIM ImmunoTech shares rise on news of pancreatic cancer research partnership with AstraZeneca and Erasmus Medical CenterJanuary 9, 2023 | tmcnet.comAIM ImmunoTech Broadens Patent Portfolio with New NetherlandsJanuary 9, 2023 | proactiveinvestors.comAIM ImmunoTech broadens patent portfolio with new Netherlands utility patentJanuary 5, 2023 | benzinga.comAIM ImmunoTech, InnSuites Hospitality Trust And 2 Other Penny Stocks Insiders Are Aggressively BuyingJanuary 5, 2023 | tmcnet.comAIM ImmunoTech to Present at the 'Virtual Investor 2023 Companies to Watch Event'January 5, 2023 | finance.yahoo.comAIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’December 28, 2022 | msn.comAIM ImmunoTech's Return On Capital Employed InsightsDecember 19, 2022 | msn.comWhy Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving PremarketDecember 12, 2022 | proactiveinvestors.comAIM ImmunoTech promotes Christopher McAleer to the role of scientific officerDecember 8, 2022 | proactiveinvestors.comAIM ImmunoTech reports positive safety, tolerability, and biological activity data from Phase 1 Ampligen studyDecember 8, 2022 | finance.yahoo.comAIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy SubjectsNovember 15, 2022 | proactiveinvestors.comAIM ImmunoTech says cash position expected to fund operations through end of 2023November 15, 2022 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 14, 2022 | proactiveinvestors.comAIM ImmunoTech shows positive results using Ampligen in treating triple negative breast cancerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address AIM Company Calendar Last Earnings11/16/2021Today3/20/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:AIM CUSIPN/A CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees21Year Founded1990Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,130,000.00 Net Margins-15,598.51% Pretax Margin-15,598.51% Return on Equity-42.06% Return on Assets-40.00% Debt Debt-to-Equity RatioN/A Current Ratio14.21 Quick Ratio14.21 Sales & Book Value Annual Sales$135,000.00 Price / Sales171.55 Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book0.40Miscellaneous Outstanding Shares48,049,000Free Float48,039,000Market Cap$23.16 million OptionableNot Optionable Beta-0.24 Social Links Key ExecutivesThomas Kenwood EquelsExecutive Vice Chairman, President & CEOPeter W. RodinoCOO, Secretary & General CounselRobert DickeyChief Financial OfficerDavid R. StrayerChief Medical OfficerChristopher McAleerChief Scientific OfficerKey CompetitorsERYTECH PharmaNASDAQ:ERYPGenetic TechnologiesNASDAQ:GENECASI PharmaceuticalsNASDAQ:CASIInhibikase TherapeuticsNYSE:IKTHarpoon TherapeuticsNASDAQ:HARPView All CompetitorsInsiders & InstitutionsMorgan StanleySold 481,800 shares on 2/15/2023Ownership: 1.908%Thomas K EquelsBought 161,291 shares on 1/3/2023Total: $50,000.21 ($0.31/share)Stewart AppelrouthBought 80,646 shares on 1/3/2023Total: $25,000.26 ($0.31/share)View All Insider TransactionsView All Institutional Transactions AIM Stock - Frequently Asked Questions How have AIM shares performed in 2023? AIM ImmunoTech's stock was trading at $0.3119 on January 1st, 2023. Since then, AIM shares have increased by 54.5% and is now trading at $0.4820. View the best growth stocks for 2023 here. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) announced its earnings results on Tuesday, November, 16th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The business earned $0.03 million during the quarter. AIM ImmunoTech had a negative net margin of 15,598.51% and a negative trailing twelve-month return on equity of 42.06%. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX). What is AIM ImmunoTech's stock symbol? AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM." Who are AIM ImmunoTech's major shareholders? AIM ImmunoTech's stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (1.91%). Insiders that own company stock include Stewart Appelrouth, Thomas K Equels and Thomas K Equels. View institutional ownership trends. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AIM ImmunoTech's stock price today? One share of AIM stock can currently be purchased for approximately $0.48. How much money does AIM ImmunoTech make? AIM ImmunoTech (NYSE:AIM) has a market capitalization of $23.16 million and generates $135,000.00 in revenue each year. The company earns $-19,130,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. How can I contact AIM ImmunoTech? AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The official website for the company is aimimmuno.com. The company can be reached via phone at (352) 448-7797, via email at ir@aimimmuno.com, or via fax at 215-988-1739. This page (NYSE:AIM) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.